NCT03119883View on ClinicalTrials.gov

Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma

NACompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

June 2, 2017

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions
Monoclonal Gammopathy of Undetermined SignificancePlasma Cell Myeloma
Interventions
OTHER

5-Carbon C 13-labeled Glutamine

Given IV

PROCEDURE

Biospecimen Collection

Undergo collection of blood

PROCEDURE

Biospecimen Collection

Undergo collection of bone marrow aspirate samples

OTHER

Uniformly-labeled [13C]glucose

Given IV

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER